VBI Vaccines, Inc. (NASDAQ:VBIV) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Friday. The firm presently has a $4.75 price objective on the biopharmaceutical company’s stock. Zacks Investment Research‘s target price would suggest a potential upside of 5.32% from the company’s current price.

According to Zacks, “VBI Vaccines Inc. is a biopharmaceutical company developing novel technologies to expand vaccine protection. The company’s eVLP vaccine platform allows for the design of enveloped virus-like particle vaccines which closely mimic the target virus. Its lead eVLP asset is a prophylactic cytomegalovirus vaccine. Its second platform is a thermostable technology that enables the development of vaccines and biologics. VBI Vaccines Inc., formerly known as SciVac Therapeutics, Inc., is headquartered in Cambridge, MA. “

Several other brokerages have also recently issued reports on VBIV. TheStreet cut shares of VBI Vaccines from a “c-” rating to a “d+” rating in a research note on Wednesday, May 31st. Noble Financial reaffirmed a “buy” rating on shares of VBI Vaccines in a research note on Monday, May 15th. Four equities research analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and an average target price of $5.38.

Shares of VBI Vaccines (VBIV) remained flat at $4.51 during mid-day trading on Friday. 1,561 shares of the stock traded hands. The company has a 50-day moving average of $4.31 and a 200 day moving average of $4.30. The company’s market capitalization is $180.67 million. VBI Vaccines has a one year low of $2.75 and a one year high of $6.60.

ILLEGAL ACTIVITY WARNING: “VBI Vaccines, Inc. (VBIV) Stock Rating Upgraded by Zacks Investment Research” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://www.americanbankingnews.com/2017/06/16/vbi-vaccines-inc-vbiv-stock-rating-upgraded-by-zacks-investment-research.html.

Institutional investors have recently made changes to their positions in the company. Goldman Sachs Group Inc. acquired a new position in shares of VBI Vaccines during the first quarter valued at about $383,000. KCG Holdings Inc. acquired a new position in shares of VBI Vaccines during the first quarter valued at about $512,000. Morgan Stanley boosted its position in shares of VBI Vaccines by 28,153.6% in the first quarter. Morgan Stanley now owns 62,723 shares of the biopharmaceutical company’s stock valued at $344,000 after buying an additional 62,501 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of VBI Vaccines by 31.0% in the first quarter. Geode Capital Management LLC now owns 22,468 shares of the biopharmaceutical company’s stock valued at $123,000 after buying an additional 5,317 shares in the last quarter. Finally, EAM Investors LLC acquired a new position in shares of VBI Vaccines during the first quarter valued at about $414,000. 29.18% of the stock is currently owned by institutional investors.

VBI Vaccines Company Profile

VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.

Get a free copy of the Zacks research report on VBI Vaccines (VBIV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for VBI Vaccines Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines Inc. and related companies with MarketBeat.com's FREE daily email newsletter.